MX370149B - Inhibidores de la expresión o función de smad7 para usarse en el tratamiento de diabetes y/o la promoción de la supervivencia de islotes pancreáticos después del trasplante. - Google Patents
Inhibidores de la expresión o función de smad7 para usarse en el tratamiento de diabetes y/o la promoción de la supervivencia de islotes pancreáticos después del trasplante.Info
- Publication number
- MX370149B MX370149B MX2014012650A MX2014012650A MX370149B MX 370149 B MX370149 B MX 370149B MX 2014012650 A MX2014012650 A MX 2014012650A MX 2014012650 A MX2014012650 A MX 2014012650A MX 370149 B MX370149 B MX 370149B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- transplantation
- treating diabetes
- pancreatic islets
- promoting survival
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625904P | 2012-04-18 | 2012-04-18 | |
| PCT/US2013/037150 WO2013158868A1 (en) | 2012-04-18 | 2013-04-18 | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014012650A MX2014012650A (es) | 2015-04-08 |
| MX370149B true MX370149B (es) | 2019-12-03 |
Family
ID=48326412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014012650A MX370149B (es) | 2012-04-18 | 2013-04-18 | Inhibidores de la expresión o función de smad7 para usarse en el tratamiento de diabetes y/o la promoción de la supervivencia de islotes pancreáticos después del trasplante. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10081809B2 (enExample) |
| EP (1) | EP2839004B1 (enExample) |
| JP (2) | JP6348484B2 (enExample) |
| KR (1) | KR20150003824A (enExample) |
| CN (2) | CN107252492A (enExample) |
| AU (1) | AU2013249191B2 (enExample) |
| CA (1) | CA2870547A1 (enExample) |
| DK (1) | DK2839004T3 (enExample) |
| ES (1) | ES2732252T3 (enExample) |
| IN (1) | IN2014DN08158A (enExample) |
| MX (1) | MX370149B (enExample) |
| NZ (1) | NZ630914A (enExample) |
| RU (1) | RU2667960C2 (enExample) |
| WO (1) | WO2013158868A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| RU2593939C2 (ru) | 2008-11-13 | 2016-08-10 | Ногра Фарма Лимитед | Антисмысловые композиции и способы их получения и применения |
| JP6389122B2 (ja) | 2011-09-15 | 2018-09-12 | ノグラ ファーマ リミテッド | 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 |
| MX370149B (es) | 2012-04-18 | 2019-12-03 | Nogra Pharma Ltd | Inhibidores de la expresión o función de smad7 para usarse en el tratamiento de diabetes y/o la promoción de la supervivencia de islotes pancreáticos después del trasplante. |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| EP2940115B1 (en) * | 2014-04-30 | 2018-10-17 | The Procter and Gamble Company | Cleaning composition |
| CA2948411A1 (en) | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| ES2718380T3 (es) * | 2015-10-29 | 2019-07-01 | Procter & Gamble | Composición detergente líquida |
| EP3162878A1 (en) * | 2015-10-29 | 2017-05-03 | The Procter and Gamble Company | Liquid detergent composition |
| US11162097B2 (en) | 2016-02-23 | 2021-11-02 | Nogra Pharma Limited | Methods of treating intestinal fibrosis using SMAD7 inhibition |
| WO2019217571A1 (en) * | 2018-05-08 | 2019-11-14 | University Of Miami | Materials and methods for the delivery of therapeutic nucleic acids to tissues |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| EP1456380B1 (en) | 2001-11-02 | 2012-04-18 | Giuliani International Limited | Smad7 inhibitors for the treatment of cns diseases |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| WO2005014782A2 (en) | 2003-06-13 | 2005-02-17 | Alnylam Europe Ag., | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| ITRM20030393A1 (it) * | 2003-08-11 | 2005-02-12 | Giuliani Spa | Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb. |
| GB0326778D0 (en) | 2003-11-18 | 2003-12-24 | Imp College Innovations Ltd | Biological materials and uses thereof |
| AU2005288522B2 (en) | 2004-09-28 | 2012-06-28 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| RU2434942C2 (ru) * | 2004-09-28 | 2011-11-27 | Кварк Фармасьютикалс, Инк. | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний |
| WO2007039151A1 (en) | 2005-09-28 | 2007-04-12 | Universität Zürich | Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases |
| DK2281042T3 (en) | 2008-04-18 | 2015-11-09 | Baxter Int | Microsphere-based composition for preventing and / or deletion of starting autoimmune diabetes |
| RU2593939C2 (ru) * | 2008-11-13 | 2016-08-10 | Ногра Фарма Лимитед | Антисмысловые композиции и способы их получения и применения |
| JP6389122B2 (ja) | 2011-09-15 | 2018-09-12 | ノグラ ファーマ リミテッド | 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 |
| MX370149B (es) | 2012-04-18 | 2019-12-03 | Nogra Pharma Ltd | Inhibidores de la expresión o función de smad7 para usarse en el tratamiento de diabetes y/o la promoción de la supervivencia de islotes pancreáticos después del trasplante. |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| CN105008394B (zh) | 2013-03-15 | 2021-10-22 | 诺格尔制药有限公司 | 治疗结肠直肠癌的方法 |
| CA2948411A1 (en) | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| EP3213070A2 (en) | 2014-10-17 | 2017-09-06 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| JP2018531936A (ja) | 2015-09-30 | 2018-11-01 | ノグラ ファーマ リミテッド | バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法 |
| CA3014383A1 (en) | 2016-02-24 | 2017-08-31 | Nogra Pharma Limited | Methods of treating celiac disease using smad7 inhibition |
| US20190328770A1 (en) | 2016-12-30 | 2019-10-31 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis |
-
2013
- 2013-04-18 MX MX2014012650A patent/MX370149B/es active IP Right Grant
- 2013-04-18 KR KR1020147032172A patent/KR20150003824A/ko not_active Abandoned
- 2013-04-18 NZ NZ630914A patent/NZ630914A/en not_active IP Right Cessation
- 2013-04-18 WO PCT/US2013/037150 patent/WO2013158868A1/en not_active Ceased
- 2013-04-18 IN IN8158DEN2014 patent/IN2014DN08158A/en unknown
- 2013-04-18 EP EP13721452.4A patent/EP2839004B1/en active Active
- 2013-04-18 DK DK13721452.4T patent/DK2839004T3/da active
- 2013-04-18 JP JP2015507173A patent/JP6348484B2/ja not_active Expired - Fee Related
- 2013-04-18 CA CA2870547A patent/CA2870547A1/en not_active Abandoned
- 2013-04-18 RU RU2014146170A patent/RU2667960C2/ru not_active IP Right Cessation
- 2013-04-18 CN CN201710440085.9A patent/CN107252492A/zh active Pending
- 2013-04-18 US US14/394,999 patent/US10081809B2/en not_active Expired - Fee Related
- 2013-04-18 ES ES13721452T patent/ES2732252T3/es active Active
- 2013-04-18 CN CN201380020520.2A patent/CN104487574B/zh not_active Expired - Fee Related
- 2013-04-18 AU AU2013249191A patent/AU2013249191B2/en not_active Ceased
-
2018
- 2018-05-31 JP JP2018104372A patent/JP2018131468A/ja active Pending
- 2018-08-10 US US16/100,906 patent/US10443056B2/en not_active Expired - Fee Related
-
2019
- 2019-09-04 US US16/559,974 patent/US20200239884A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015514778A (ja) | 2015-05-21 |
| CN104487574B (zh) | 2017-07-07 |
| EP2839004B1 (en) | 2019-06-12 |
| CA2870547A1 (en) | 2013-10-24 |
| US20200239884A1 (en) | 2020-07-30 |
| US20190136237A1 (en) | 2019-05-09 |
| HK1207117A1 (en) | 2016-01-22 |
| CN107252492A (zh) | 2017-10-17 |
| RU2667960C2 (ru) | 2018-09-25 |
| RU2014146170A (ru) | 2016-06-10 |
| JP2018131468A (ja) | 2018-08-23 |
| IN2014DN08158A (enExample) | 2015-05-01 |
| ES2732252T3 (es) | 2019-11-21 |
| CN104487574A (zh) | 2015-04-01 |
| WO2013158868A1 (en) | 2013-10-24 |
| DK2839004T3 (da) | 2019-07-01 |
| AU2013249191B2 (en) | 2019-01-03 |
| US10443056B2 (en) | 2019-10-15 |
| AU2013249191A1 (en) | 2014-10-09 |
| NZ630914A (en) | 2017-01-27 |
| MX2014012650A (es) | 2015-04-08 |
| US10081809B2 (en) | 2018-09-25 |
| JP6348484B2 (ja) | 2018-06-27 |
| US20150315573A1 (en) | 2015-11-05 |
| EP2839004A1 (en) | 2015-02-25 |
| KR20150003824A (ko) | 2015-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014012650A (es) | Inhibidores de la expresión o función de smad7 para usarse en el tratamiento de diabetes y/o la promoción de la supervivencia de islotes pancreáticos después del trasplante. | |
| UA118328C2 (uk) | Спосіб інтегрування екзогенних послідовностей у геном рослинної клітини | |
| SG10201906304TA (en) | Use of perfusion decellularized liver for islet cell recellularization | |
| WO2011130402A3 (en) | Hepatocyte production by forward programming | |
| WO2009137844A3 (en) | Pancreatic endocrine progenitor cells derived from pluripotent stem cells | |
| PH12015500433B1 (en) | Methods and compositions for treatment of a genetic condition | |
| MY159971A (en) | Multipotent/pluripotent cells and methods | |
| PH12013500827A1 (en) | Chromobacterium bioactive compositions and metabolites | |
| IN2012DN00568A (enExample) | ||
| MX2013001045A (es) | Organoide hepatico, sus usos y metodo de cultivo para obtenerlos. | |
| PH12014502588A1 (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| JO3450B1 (ar) | أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز | |
| HK1218139A1 (zh) | 去分化的重新編程細胞所衍生的細胞組合物 | |
| UA115652C2 (uk) | Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21 | |
| PH12013500199A1 (en) | Treatment of diabetes with pancreatic endocrine precursor cells | |
| MX2014013752A (es) | Inhibidores de nampt. | |
| MX359769B (es) | Metodos para descelularizar huesos. | |
| PH12014502513A1 (en) | Nampt inhibitors | |
| MX348311B (es) | Inhibidores nampt. | |
| CR20150543A (es) | Método de tratamiento de páncreas e hígado para condiciones por transplante de células madre en paredes de conducto biliar | |
| MX2013006165A (es) | Fibras de degradacion controlada. | |
| SG11201408717XA (en) | Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus | |
| EP3202409A4 (en) | Composition, cell construct, islet transplant kit, islet cell transplant therapeutic agent and blood sugar reducing agent, composition including islets, kit including islets, and islet transplant therapeutic agent and blood sugar reducing agent | |
| MX2014006157A (es) | Moduladores mejoradores de la actividad de hec1 y metodos para los mismos. | |
| UY34070A (es) | Método y composición para tratamiento de semillas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |